SLN Silence Therapeutics plc: institutional ownership and insider trading

77 funds reported holding $253M of Silence Therapeutics plc in their latest 13F filings; in Q2 2026 funds net bought $32.3M, with 20 new positions and 4 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $615K and net income of −$60.0M.

SLN revenue and earnings

Famous investors holding SLN

Largest institutional holders of SLN

  1. Siren, L.L.C. — $36.4M
  2. TCG Crossover Management, LLC — $33.3M
  3. Redmile Group, LLC — $23.8M
  4. Nantahala Capital Management, LLC — $14.8M
  5. CITADEL ADVISORS LLC — $14.6M
  6. TFG Asset Management GP Ltd — $11.7M
  7. Nextech Invest, Ltd. — $10.5M
  8. MILLENNIUM MANAGEMENT LLC — $9.98M
  9. Soleus Capital Management, L.P. — $6.92M
  10. BALYASNY ASSET MANAGEMENT L.P. — $6.71M

5%+ owners

Who owns the most SLN stock?

The largest institutional holders of Silence Therapeutics plc in the latest 13F filings are Siren, L.L.C. ($36.4M), TCG Crossover Management, LLC ($33.3M), Redmile Group, LLC ($23.8M).

Are insiders buying or selling SLN?

No open-market insider buys or sells of Silence Therapeutics plc were reported in the last 12 months.

Which famous investors own SLN?

Ken Griffin, Izzy Englander, Two Sigma, Renaissance Technologies.

What was SLN's revenue last quarter?

Silence Therapeutics plc reported revenue of $0 for the quarter ended June 30, 2026, with net income of −$12.3M.

Which ETFs hold SLN?

3 ETFs and mutual funds hold it among their top 100 positions, including FBTAX, AGSCX, AISZX.

All SLN 13F holders · All SLN insider trades